Supplementary Table S2. Updated adverse event overview.

	Abemaciclib + Trastuzumab + Fulvestrant (Arm A) (N=78)		Abemaciclib + Trastuzumab (Arm B) (N=77)		Trastuzumab + Chemotherapy (Arm C) (N=72)		Total (N=227)	
Number of Subjects[a]	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**
Subjects with ≥1 TEAE	77	98.7	76	98.7	68	94.4	221	97.4
Related to study treatment[b]	73	93.6	69	89.6	60	83.3	202	89.0
Subjects with ≥1 CTCAE Grade ≥3 TEAE	59	75.6	43	55.8	39	54.2	141	62.1
Related to study treatment[b]	45	57.7	31	40.3	25	34.7	101	44.5
Subjects with ≥1 SAE	24	30.8	15	19.5	14	19.4	53	23.3
Related to study treatment[b]	8	10.3	4	5.2	5	6.9	17	7.5
Subjects who discontinued study treatment due to AE	11	14.1	13	16.9	7	9.7	31	13.7
Related to study treatment[b]	6	7.7	10	13.0	5	6.9	21	9.3
Subjects who discontinued study treatment due to SAE	4	5.1	2	2.6	3	4.2	9	4.0
Related to study treatment[b]	1	1.3	2	2.6	2	2.8	5	2.2
Subjects who died due to AE on study treatment[c]	3	3.8	1	1.3	1	1.4	5	2.2
Related to study treatment[b]	0	0.0	1	1.3	1	1.4	2	0.9
Subjects who died due to AE within 30 days of discontinuation from study treatment[c]	1	1.3	0	0	0	0.0	1	0.4
Related to study treatment[b]	0	0.0	0	0	0	0.0	0	0.0

Abbreviations: N = number of subjects in safety population; n = number of subjects in the specified category; CTCAE = Common Terminology Criteria for Adverse Events; TEAE = treatment-emergent adverse event; MedDRA = Medical Dictionary for Regulatory Activities; AE = adverse event; SAE = serious adverse event.

[a] Subjects may be counted in more than 1 category.

[b] Includes events that were considered related to study treatment as judged by the investigator.

[c] Deaths are also included as SAEs and discontinuations due to AEs.

MedDRA Version 24.1; CTCAE Version 4.